Patent intelligence · US
US 10370349
Functionalised benzopyran compounds and use thereof
Functionalised benzopyran compounds and use thereof
Patent details — US 10370349
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 6, 2019
- Expiration
- Aug 1, 2039
- Applicant
- Kazia Therapeutics Limited
- Claims
- 8
- CPC classes
- A61P, A61P35/00, A61P35/04
Quick answer
US 10370349 (Functionalised benzopyran compounds and use thereof) is held by Kazia Therapeutics Limited. Status: granted. Granted Aug 6, 2019. Expires Aug 1, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kazia Therapeutics Limited
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61P, A61P35/00, A61P35/04
Related coverage
5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis
In May 2026, the FDA granted five major oncology approvals, including a first-in-class combination for non-muscle invasive bladder cancer. This analysis covers the approvals, their competitive impact, and next milestones for pharma teams.
Generic Oncology Drugs in Egypt: Market Analysis & Regional Impact
This article delves into the market dynamics of generic oncology drugs in Egypt, highlighting their role in cancer treatment and regional healthcare impact.
Frequently asked questions
What is US patent 10370349?
US 10370349 (Functionalised benzopyran compounds and use thereof) is held by Kazia Therapeutics Limited. Status: granted. Granted Aug 6, 2019. Expires Aug 1, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10370349?
Kazia Therapeutics Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 10370349 expire?
Our index shows an expiration date of Aug 1, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.